DiscoverNewsRamp Science, Exploration and Discovery PodcastAdvancements in Rare Disease Therapies: Zevra Therapeutics and Clene Inc. Updates
Advancements in Rare Disease Therapies: Zevra Therapeutics and Clene Inc. Updates

Advancements in Rare Disease Therapies: Zevra Therapeutics and Clene Inc. Updates

Update: 2025-08-29
Share

Description

Zevra Therapeutics presents new data on MIPLYFFA targeting Niemann-Pick disease type C at a congress, while Clene Inc. focuses on neurodegenerative diseases with lead candidate CNM-Au8® for ALS, gearing up for a Phase 3 trial and having a late-stage MS program. Both companies offer innovative approaches to treating rare diseases with significant investment potential.
Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Advancements in Rare Disease Therapies: Zevra Therapeutics and Clene Inc. Updates

Advancements in Rare Disease Therapies: Zevra Therapeutics and Clene Inc. Updates

NewsRamp